CareRx Corporation

TSX:CRRX.TO

Medical - Care Facilities

Healthcare
$3.21 +0.63%

+$0.02 today

Market cap
$203.06M
Beta
0.62
P/E (TTM)
7.4
EPS (TTM)
$0.43
Dividend yield
1.88%
52W Low $2.70High $4.00

Volume 0.01M

Average 0.04M

CRRX.TO EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

CareRx CorporationTSX: CRRX.TO

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA grows, but more slowly than its trailing trend

Q1 FY2026 EBITDA of CA$7.96M rose 17.7% year over year, behind the +25.2% change in trailing-twelve-month EBITDA. Sequentially, it rose 5.6% from the prior quarter.

Context

  • EBITDA amounted to 8.2% of revenue in FY2025, up 1.6 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of CA$31.66M (+4.8%) for the fiscal year ending Dec 2026, a slowdown from the +26.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$7.96M+5.6% QoQ
Last fiscal yearDec 2025
CA$30.22M+26.4% YoY
LTMMar 2026
CA$30.12M+25.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.7%+12.1%-5.6 pp
1 year+26.4%+4.8%-21.6 pp
3-year CAGR—+8.9%—
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

CAD · from the income statement

Latest · FY2025
30.22M CAD
Year-over-year change
+26.4%
4-year CAGR
+35.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CRRX.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +25.2% is the 3rd highest of 6, against a peer median of +21.8%.
  • EBITDA amounts to 8.0% of revenue for CRRX.TO, versus a peer median of 31.5%.
CRRX.TO Competitors
EBITDA for CRRX.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DR.TOMedical Facilities CorporationLTM Mar 2026$75.52M USD-3.6%+5.1%24.7%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$49.15M CAD+45.8%—31.0%
CRRX.TOCareRx CorporationLTM Mar 2026CA$30.12M CAD+25.2%—8.0%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$17.79M USD+21.8%+0.0%31.9%
HBP.TOHelix BioPharma Corp.LTM Apr 2026-CA$3.08M CAD+67.7%——
PRN.TOProfound Medical Corp.LTM Mar 2026-$36.45M USD-1.4%—194.3%
Peer median (excluding CRRX.TO) —+21.8%+2.6%31.5%

Competitors are the stored peer set for CRRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue262.63M381.73M370.75M366.71M370.24M
Cost of Revenue187.35M271.79M286.02M258.65M277.61M
Gross Profit75.28M109.93M84.72M108.06M92.63M
Gross Margin28.7%28.8%22.9%29.5%25.0%
Research & Development00000
Selling, General & Admin70.52M102.55M77.5M32.75M34.23M
Operating Expenses70.47M82.24M100.03M103.54M80.75M
Depreciation & Amortization15.39M20.07M19.98M19.19M18.33M
EBITDA9.01M(610K)24.65M23.9M30.22M
EBITDA Margin3.4%-0.2%6.6%6.5%8.2%
Operating Income(3.31M)(21.94M)4.67M4.53M11.88M
Operating Margin-1.3%-5.7%1.3%1.2%3.2%
Interest Income58K278K1.26M63K161K
Interest Expense17.35M15.22M14.27M9.18M6.84M
Other Income / Expenses(20.43M)(13.95M)(14.27M)(8.99M)(8.53M)
Income Before Tax(23.74M)(35.9M)(9.6M)(4.47M)3.35M
Pre-Tax Margin-9.0%-9.4%-2.6%-1.2%0.9%
Income Tax Expense(1.01M)(1.54M)(4.19M)32K(22.77M)
Net Income(22.73M)(34.35M)(5.41M)(4.5M)26.13M
Net Margin-8.7%-9.0%-1.5%-1.2%7.1%
EPS (Basic)(0.65)(0.72)(0.09)(0.07)0.42
EPS (Diluted)(0.65)(0.72)(0.09)(0.07)0.41
Weighted Avg Shares34.86M47.6M57.35M60.25M62.73M
Weighted Avg Shares (Diluted)34.86M47.6M57.35M60.25M64.49M

CareRx Corporation

TSX:CRRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$3.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.